Relapsing Remitting Multiple Sclerosis Clinical Trials

325 clinical trials for Relapsing Remitting Multiple Sclerosis across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis — RECRUITING · PHASE3
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study — RECRUITING · NA
• A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis — RECRUITING · PHASE3
• A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis — RECRUITING · PHASE3
• ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS — RECRUITING · PHASE4
• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. — RECRUITING · PHASE3
• Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis — RECRUITING · NA
• A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis — RECRUITING · PHASE3
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — RECRUITING · PHASE3
• Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies — RECRUITING
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis — RECRUITING · PHASE1
• Effect of noninvasive transcutaneous auricular vagus nerve stimulation (taVNS) on processing speed in multiple sclerosis. — RECRUITING
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis — RECRUITING
• Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis — RECRUITING
• Rituximab and Ocrelizumab in Serum With Multiple Sclerosis — RECRUITING
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis — RECRUITING · PHASE3
• Investigation of Subclinical Markers of Multiple Sclerosis — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY, COMPARING THE EFFICACY AND SAFETY OF REMIBRUTINIB VERSUS TERIFLUNOMIDE IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS, FOLLOWED BY EXTENDED TREATMENT WITH OPEN-LABEL REMIBRUTINIB — RECRUITING
• AN OPEN-LABEL, SINGLE ARM, MULTI-CENTER EXTENSION STUDY EVALUATING LONG-TERM SAFETY, TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS — RECRUITING
• AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS — RECRUITING
• A PHASE 3B, 12-MONTH, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB019, DACLIZUMAB, IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) SWITCHING FROM NATALIZUMAB (SUSTAIN) — RECRUITING · PHASE3
• To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS). — ACTIVE_NOT_RECRUITING · PHASE3
• Regulation of the stress-axis by vitamin D in subjects with multiple sclerosis. — TERMINATED · PHASE2
• Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. — COMPLETED · PHASE2
• A clinical study to find out whether Copaxone (glatiramer acetate 40mg/ 1 ml), injected three times a week, is effective and safe for the treatment of multiple sclerosis. The safety and efficacy of Copaxone is compared to placebo (control treatment without therapeutically active drug). — COMPLETED · PHASE3
• A study designed to determine safety and efficacy of Daclizumab High Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have Completed Treatment in a previous study, 205MS202 (SELECTION) — COMPLETED · PHASE2
• A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis — COMPLETED · PHASE1
• A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) "Estudio fase IIa, aleatorizado, doble ciego, controlado con placebo, de BGC20-0134 administrado de forma oral en pacientes con esclerosis múltiple recurrente remitente (EMRR)” — TERMINATED · PHASE2
• A clinical extension study to evaluate the safety, tolerability and efficacy of AIN457 in multiple sclerosis patients with relapses — TERMINATED · PHASE2
• A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis — COMPLETED · PHASE3
• A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate — COMPLETED · PHASE3
• Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis — COMPLETED · PHASE2
• INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS — COMPLETED · PHASE2
• A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis — COMPLETED · PHASE2
• A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. — COMPLETED · PHASE3
• A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS). — COMPLETED · PHASE2
• Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis — COMPLETED · PHASE4
• A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis — COMPLETED · PHASE2
• An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT) — COMPLETED · PHASE2
• A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy — COMPLETED · PHASE3
• P2-IMU-838-MS - Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsingremitting multiple sclerosis (RRMS) (EMPhASIS) — TERMINATED · PHASE2
• A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) — NOT_YET_RECRUITING · PHASE2
• WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE1
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis — SUSPENDED
• Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis — COMPLETED · PHASE2
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) — ACTIVE_NOT_RECRUITING · PHASE3
• An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis — NOT_YET_RECRUITING · PHASE2
• PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis — NOT_YET_RECRUITING · NA
• Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE3

Refine this search